Zotatifin

also known as eFT226 · Zotatifina · Zotatifine

Small molecule targets EIF4A1 via inhibition

Developed for: cancer · estrogen-receptor positive breast cancer · Her2-receptor negative breast cancer · COVID-19
Investigated by: Effector Therapeutics · Jennifer Lee Caswell-Jin · Novartis Pharmaceuticals · United States Department of Defense

today NCT05101564 · Ph 2 NCT04092673 · Ph 1/2

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/21 trial
Phase 1/2	NCT04092673	Oct 2019 → Dec 2024	cancer	Effector Therapeutics	Unknown	No outcome recorded
Phase 21 trial
Phase 2	NCT05101564	Mar 2023 → Jun 2024	Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer	Jennifer Lee Caswell-Jin	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04632381 Comparator	Jul 2021 → Jan 2023	COVID-19	Effector Therapeutics	Completed	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	Zotatifin	“Intravenous Zotatifin (eFT226) in Subjects With Selected Advanced Solid Tumor Malignancies” NCT04092673 ↗ 2 NCT05101564 ↗ NCT04632381 ↗
Known as	eFT226	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04092673 ↗
Known as	Zotatifina	ChEMBL registry synonym — accepted as the source's own label CHEMBL4303782 ↗
Known as	Zotatifine	ChEMBL registry synonym — accepted as the source's own label CHEMBL4303782 ↗
Action	Inhibit	“eIF4A1 inhibition by eFT226” NCT04092673 ↗
Modality	Small molecule	“eFT226 is a novel small-molecule, investigational drug” NCT04092673 ↗ 1 CHEMBL4303782 ↗
Route	Intravenous	“eFT226 administered IV weekly in 21-day cycles” NCT04092673 ↗
Target	EIF4A1	“eIF4A1 inhibition by eFT226 downregulates expression” NCT04092673 ↗